<DOC>
	<DOCNO>NCT02211937</DOCNO>
	<brief_summary>Study investigate relative oral bioavailability 400 mg BI 44847 suspension vs. 400 mg BI 44847 tablet , investigate food effect 400 mg tablet pharmacokinetic ( PK ) investigate relative oral bioavailability 40 mg BI 44847 solution vs. 40 mg BI 44847 tablet .</brief_summary>
	<brief_title>Relative Oral Bioavailability BI 44847 Suspension Compared Tablet Influence Food Anf BI 44847 Solution Compared Tablet Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Healthy male accord follow criterion base upon complete medical history , include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test Age ≥ 21 Age ≤ 50 year BMI ≥ 18.5 BMI ≤ 29.9 kg/m2 ( Body Mass Index ) Signed date write informed consent prior admission study accordance Good Clinical Practice local legislation Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( 100 mL ) within four week prior administration trial Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen study centre Any ECG value outside reference range clinical relevance include , limited QRS interval &gt; 120 ms. A mark baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m QT &gt; 500 m ) A history additional risk factor torsade de pointes ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) The use concomitant medication prolong QT/QTc interval</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>